Christopher W. Coyle

Christopher W. Coyle

Auto-generated profile, based on publicly available information

Christopher W. Coyle

Molecular and Systems Pharmacology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University School of Medicine, Atlanta, GA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ISIan W. Smith
Ian W. Smith
ADAnne E. D'AQuino
Anne E. D'AQuino
CCChristopher W. Coyle
Christopher W. Coyle
AFAndrew Fedanov
Andrew Fedanov
EPErnest T. Parker
Ernest T. Parker
PSPaul Clint Spiegel
Paul Clint Spiegel

27 August 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
KKKristopher Knight
Kristopher Knight
CCChristopher W. Coyle
Christopher W. Coyle
CRCaelan E. Radford
Caelan E. Radford
EPErnest T. Parker
Ernest T. Parker
AFAndrew Fedanov
Andrew Fedanov
CDChristopher B. Doering
Christopher B. Doering
Orthologous proteins contain sequence disparity guided by natural selection. In certain cases, species-specific protein functionality predicts pharmacological enhancement, such as greater specific activity or stability. However, immunological barriers generally preclude use of nonhuman proteins as therapeutics, and difficulty exists in the identification of individual sequence determinants among the overall sequence disparity. Ancestral sequence reconstruction (ASR) represents a platform for the prediction and resurrection of ancient gene and protein sequences. Recently, we demonstrated that ASR can be used as a platform to facilitate the identification of therapeutic protein variants with enhanced properties. Specifically, we identified coagulation factor VIII (FVIII) variants with improved specific activity, biosynthesis, stability, and resistance to anti-human FVIII antibody–based inhibition. In the current study, we resurrected a panel of ancient mammalian coagulation factor IX (FIX) variants with the goal of identifying improved pharmaceutical candidates. One variant (An96) demonstrated 12-fold greater FIX activity production than human FIX. Addition of the R338L Padua substitution further increased An96 activity, suggesting independent but additive mechanisms. after adeno-associated virus 2 (AAV2)/8-FIX gene therapy, 10-fold greater plasma FIX activity was observed in hemophilia B mice administered AAV2/8-An96–Padua as compared with AAV2/8-human FIX–Padua. Furthermore, phenotypic correction conferred by the ancestral variant was confirmed using a saphenous vein bleeding challenge and thromboelastography. Collectively, these findings validate the ASR drug discovery platform as well as identify an ancient FIX candidate for pharmaceutical development.

5 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
PZPhilip M. Zakas
Philip M. Zakas
CCChristopher W. Coyle
Christopher W. Coyle
ABAnja Brehm
Anja Brehm
MBMarion Bayer
Marion Bayer
BSBarbara Solecka-Witulska
Barbara Solecka-Witulska
DLDavid Lillicrap
David Lillicrap
Ancestral sequence reconstruction provides a unique platform for investigating the molecular evolution of single gene products and recently has shown success in engineering advanced biological therapeutics. To date, the coevolution of proteins within complexes and protein–protein interactions is mostly investigated in silico via proteomics and/or within single-celled systems. Herein, ancestral sequence reconstruction is used to investigate the molecular evolution of 2 proteins linked not only by stabilizing association in circulation but also by their independent roles within the primary and secondary hemostatic systems of mammals. Using sequence analysis and biochemical characterization of recombinant ancestral von Willebrand factor (VWF) and coagulation factor VIII (FVIII), we investigated the evolution of the essential macromolecular FVIII/VWF complex. Our data support the hypothesis that these coagulation proteins coevolved throughout mammalian diversification, maintaining strong binding affinities while modulating independent and distinct hemostatic activities in diverse lineages.